RECRUITING

Don't Treat Ghosts Anti-MRSA Antibiotics in Osteomyelitis Without Identified MRSA

Conditions

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

Osteomyelitis is described as infection and inflammation of the long bone or bone marrow, often due to an open wound, operation, or invasive trauma.1 It is invasive and involves hematogenous seeding or contiguous spread of the infectious organism

Official Title

Don't Treat Ghosts: Anti-MRSA Antibiotics in Osteomyelitis Without Identified MRSA

Quick Facts

Study Start:2023-06-23
Study Completion:2024-06-23
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT06096012

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years to 75 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:No
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. * • Admission to any MHS hospital between April 1, 2017 and April 1, 2023
  2. * \> 18 years of age
  3. * Documented osteomyelitis location of the lower limb via ICD-10 code
  4. * Documented imaging of lower limb osteomyelitis during index admission
  5. * Planned intravenous (IV) antibiotics for at least 4 weeks
  1. * • IV antibiotics for less than 24 hours inpatient
  2. * Planned surgical intervention documented at admission
  3. * Patients receiving monotherapy with an anti-MRSA agent
  4. * Positive MRSA culture during index admission
  5. * Current outpatient antibiotic use on index admission
  6. * Repeated hospital admission during study period

Contacts and Locations

Study Contact

Bethany Brauer, MPH
CONTACT
214-947-4681
MHSIRB@mhd.com
Colette Ngo Ndjom, MS
CONTACT
214-947-4681
mhsirb@mhd.com

Principal Investigator

Matthew Crotty, PharmD
PRINCIPAL_INVESTIGATOR
Methodist Dallas Medical Center

Study Locations (Sites)

Methodist Dallas Medical Center
Dallas, Texas, 75203
United States

Collaborators and Investigators

Sponsor: Methodist Health System

  • Matthew Crotty, PharmD, PRINCIPAL_INVESTIGATOR, Methodist Dallas Medical Center

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2023-06-23
Study Completion Date2024-06-23

Study Record Updates

Study Start Date2023-06-23
Study Completion Date2024-06-23

Terms related to this study

Additional Relevant MeSH Terms

  • Osteomyelitis